Pluri Inc. (PLUR)
Oxford Ledge is still expanding full research coverage of PLUR. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Pluri develops and manufactures cell-based products and services across regenerative medicine, immunotherapy, food technology, and agriculture sectors.
SEC filings
- 8-K Delisting / transfer of listing 2026-07-13
- 8-K Entry into material agreement; Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-22
- 8-K Other material event 2026-06-01
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- DEF 14A Proxy statement for shareholder vote 2026-04-23
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for PLUR. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open PLUR in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.